Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options

During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in <i>EGFR</i> and translocations in <i>ALK</i> and <i>ROS1</i> have identified subsets of patients with excellent tumor response to oral targ...

Full description

Bibliographic Details
Main Authors: Arpita Desai, Smitha P. Menon, Grace K. Dy
Format: Article
Language:English
Published: China Anti-Cancer Association 2016-03-01
Series:Cancer Biology & Medicine
Subjects:
RAS
RAF
MEK
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/910
id doaj-d09a5e7041374abfad9cf1d1e7f7bc42
record_format Article
spelling doaj-d09a5e7041374abfad9cf1d1e7f7bc422020-11-25T01:18:27ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412095-39412016-03-01131778610.20892/j.issn.2095-3941.2016.00082016000008Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment optionsArpita Desai0Smitha P. Menon1Grace K. Dy2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA;Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226-0509, USADepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA;During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in <i>EGFR</i> and translocations in <i>ALK</i> and <i>ROS1</i> have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review, we highlight treatment options including corresponding clinical trials for oncogenic alterations affecting the receptor tyrosine kinases MET, FGFR, NTRK, RET, HER2, HER3, and HER4 as well as components of the RAS-RAF-MEK signaling pathway.http://www.cancerbiomed.org/index.php/cocr/article/view/910RASRAFMEKreceptor tyrosine kinases (RTK)fibroblast growth factor receptor (FGFR)non-small cell lung cance (NSCLC)
collection DOAJ
language English
format Article
sources DOAJ
author Arpita Desai
Smitha P. Menon
Grace K. Dy
spellingShingle Arpita Desai
Smitha P. Menon
Grace K. Dy
Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options
Cancer Biology & Medicine
RAS
RAF
MEK
receptor tyrosine kinases (RTK)
fibroblast growth factor receptor (FGFR)
non-small cell lung cance (NSCLC)
author_facet Arpita Desai
Smitha P. Menon
Grace K. Dy
author_sort Arpita Desai
title Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options
title_short Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options
title_full Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options
title_fullStr Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options
title_full_unstemmed Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options
title_sort alterations in genes other than <i>egfr/alk/ros1</i> in non-small cell lung cancer: trials and treatment options
publisher China Anti-Cancer Association
series Cancer Biology & Medicine
issn 2095-3941
2095-3941
publishDate 2016-03-01
description During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in <i>EGFR</i> and translocations in <i>ALK</i> and <i>ROS1</i> have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review, we highlight treatment options including corresponding clinical trials for oncogenic alterations affecting the receptor tyrosine kinases MET, FGFR, NTRK, RET, HER2, HER3, and HER4 as well as components of the RAS-RAF-MEK signaling pathway.
topic RAS
RAF
MEK
receptor tyrosine kinases (RTK)
fibroblast growth factor receptor (FGFR)
non-small cell lung cance (NSCLC)
url http://www.cancerbiomed.org/index.php/cocr/article/view/910
work_keys_str_mv AT arpitadesai alterationsingenesotherthaniegfralkros1iinnonsmallcelllungcancertrialsandtreatmentoptions
AT smithapmenon alterationsingenesotherthaniegfralkros1iinnonsmallcelllungcancertrialsandtreatmentoptions
AT gracekdy alterationsingenesotherthaniegfralkros1iinnonsmallcelllungcancertrialsandtreatmentoptions
_version_ 1725142376987492352